Amgen (NASDAQ:AMGN), a company that says it is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics, yesterday announced its financial results for the third quarter of 2019.

The company reported total revenue of USD5.7bn in the third quarter of 2019, down 3% compared to the same period in 2018.

The firm reported an increase in GAAP earnings per share of 14% to USD3.27 benefited by lower weighted-average shares outstanding and higher operating income.

The company generated USD3.2bn of free cash flow in the third quarter of 2019 versus USD3.1bn in the third quarter of 2018.

Robert A Bradway, chairman and chief executive officer, commented, 'Amgen continues to execute well in a dynamic environment, with many of our innovative medicines delivering double-digit, volume-driven growth, complemented by the strong performance of our recently launched biosimilar products.'